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Bone metastases affect a large portion of the cancer population. As treatment options continue to evolve,
many added failures and challenges arise. This narrative review details such in palliative radiation therapy for
bone metastases. We begin by describing the incidence rates of bone metastases in the cancer population,
the current standards of practice in recent literature and clinical trial data. Inconsistencies in end point
deﬁnitions along with difﬁculties in measuring response to treatment and controversial areas are outlined.
Current literature suggests that there is a discrepancy in physician and patient perspective on treatment
options as well as quality of life. The added challenges of treatment side effects are addressed and a review of
recent trials is given. Stereotactic radiation therapy is a relatively new treatment option for patients with
bone metastases. Therefore, a review of the safety and efﬁcacy of this treatment is provided. Other new areas
of bone metastases treatment and research such as high intensity focused ultrasound and nanoparticles are
discussed. Physicians need to prevent unwanted side effects of treatment in addition to determining how to
integrate many new upcoming treatment options for patients with bone metastases. A continued reluctance
to practice evidence based medicine needs to be addressed.
& 2013 Elsevier GmbH. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Bone metastases are a common complication of cancer, with
breast and prostate cancers being the most common types to
metastasize to bone [1]. 70–85% of cancer patients are diagnosed
as having bone metastases at the time of autopsy [2,3]. These bone
metastases and the primary cancer itself can cause patients great
pain and functional interference. Radiation therapy has been well
established for the treatment of symptomatic bone metastases [4].
Although radiation therapy is one of the most common treat-
ments for pain palliation in patients with bone metastases, a
number of issues exist. As the radiation oncology ﬁeld has evolved,
a number of added failures and challenges to bone metastases
research in radiation oncology have been presented. Radiation
oncologists have worked towards establishing evidence-based
treatment guidelines; however whether or not these guidelines
are followed is one area in which improvement is required. The
purpose of this review is to outline the failures and challenges
associated with bone metastases research in radiation oncology.
As new treatment options become available, radiation oncologist. This is an open access article und
ology, Odette Cancer Centre,
Avenue, Toronto, Ontario,
480 6002.
Chow).need to work collaboratively with other health care professionals
in order to deliver the most current treatments to their patients.2. Failures
2.1. Different endpoints and controversial conclusions
Many bone metastases trials have been conducted in order to
determine efﬁcacy of radiation treatment; however each trial
appears to have slightly different endpoints. With these differing
endpoints, a number of different conclusions have been drawn.
This is a major failure of bone metastases research, as results from
trials are often times contradictory.
2.1.1. Inconsistency in endpoints
A number of radiation therapy trials have been conducted over
the past few decades to determine the efﬁcacy of the palliation of
bone pain due to bone metastases. Although these studies have
been greatly beneﬁcial and inﬂuential to the radiation oncology
ﬁeld, their inconsistency in endpoint deﬁnitions has left radiation
oncologists and researchers unable to effectively compare the
results of these trials.
Even within the same patient population, endpoints have
differed. In a study by Tong et al. with the RTOG, the threeer the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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utilized [5]. Complete relief was deﬁned as the pain score dropping
to zero, partial relief deﬁned as pain score dropping below four
points and minimal relief deﬁned as pain score dropping below the
initial pain score. Whereas in a re-analysis by Blitzer et al. in the
same patient population, four endpoints were utilized: complete
pain relief (pain score falls to zero), complete pain relief prior to
retreatment (pain score falls to zero before retreatment), retreat-
ment (freedom from retreatment), and complete combined relief
(pain score and narcotic score fell to zero) [6]. Although both of
these studies included the same patient population, the conclu-
sions drawn were different due to the differing endpoint deﬁni-
tions. The study by Tong et al. concluded that low dose, short
course schedules are as effective as high dose protracted programs
[5], whereas Blitzer et al. concluded that there was an improved
complete response with protracted fractionation schedules [6].
In a Canadian trial by Kirkbride et al., yet another deﬁnition of
response rates was utilized. This trial randomized patients
between a single 8 Gy treatment and 20 Gy in 5 fractions for the
palliation of painful bone metastases. The endpoint of this trial
was the clinically signiﬁcant pain relief, as deﬁned by a reduction
in pain score at the treated site with reduced analgesics or a pain
score of zero at the treated site with no increase in analgesics at
3 months post treatment [7]. This trial was closed early; as it was
determined that 20 Gy in 5 fractions was superior for pain control
when compared to 8 Gy in 1 fraction. However, when pain score
was assessed at 3 months independent of analgesic score, the two
arms were almost identical.
The observed treatment response is also inﬂuenced by the type
of pain scale employed, the inclusion of quality of life as an
endpoint and the duration of follow-up. If very stringent criteria
are utilized, response rates reported may be lower than tradition-
ally accepted rates.
2.1.2. Difﬁculty in measuring response
An example of the differing response rates when different pain
scales are employed is observed in the Danish Bone Pain Trial. Pain
relief was assessed utilizing a categorical scale and a visual analog
scale. Using the categorical scale, an improvement of at least one
category on the 5-point scale was seen in 62% of patients at
4 weeks, whereas a 50% reduction in pain was only seen in 49% of
patients at 4 weeks using the analog scale [8]. A difference in
response rates was also seen in the timing of follow-up. Fifteen
percent of patients had a complete response at 4 weeks post
treatment, while 25% of patients had a complete response at any
time during the entire 20 week follow-up period. In this same
population, complete response dropped to 12% when “no use of
morphine” was added to the deﬁnition, and complete response
rates dropped to 4% when “complete well-being” was included in
the deﬁnition [8].
It is evident through the Danish trial and other key bone
metastases trials that there is a large inconsistency in the deﬁni-
tion of response, therefore a number of different conclusions have
been reached, many of which contradict each other. Other difﬁ-
culties in measuring response rate include the fact that radiation
therapy is a local treatment, and cancer pain can originate from
multiple sites. Other systemic treatments such as analgesics,
chemotherapy, hormonal therapy and bisphosphonates also work
at the treatment site and can contribute to the response rates seen
from radiation therapy.
2.1.3. Controversial areas
Currently, many controversial areas exist, such as the role of
analgesic use in assessing treatment response, the deﬁnition of
“partial response” and the interpretation of retreatment. Wu et al.addressed the end point inconsistency in their review of 12
randomized control trials for palliative radiotherapy. They con-
cluded that although pain relief is a consistent primary outcome, a
consensus on the features of treatment endpoints is needed to
establish common grounds for future trials [9].
In response to these inconsistencies, Chow et al. surveyed a
number of radiation oncologists and established an international
consensus on palliative radiotherapy endpoints [10]. Experts were
in agreement that pain assessment at the treatment site should be
on a scale of 0 (no pain) to 10 (maximal pain). Incorporation of
quality of life questionnaires such as the EORTC QLQ-BM22 and/or
the QLQ-C15 was recommended for all clinical trials. A period of
1 week between analgesic dosing adjustment and start of radia-
tion was also recommended to minimize risk of analgesic effects
confounding radiation treatment effects [10]. It was also recom-
mended that re-irradiation only be considered at least 4 weeks
after the radiation treatment. A consensus on response rate
deﬁnitions was also reached. A complete response was deﬁned
as a pain score of 0 at the treated site with no increase in
analgesics, while a partial response was deﬁned as a pain score
reduction of 2 or more at the treated site without an analgesic
increase, or an analgesic reduction of 25% without an increase in
pain. Pain progression was deﬁned as an increase in pain score of
2 or more above baseline at the treated site with stable analgesics,
or an analgesic increase of 25% above baseline. Lastly, an indeter-
minate response was deﬁned as any response that does not ﬁt into
any of the other three categories [10]. It was concluded that these
recommendations should be taken into consideration for all future
bone metastases trials.
In order to determine the optimal treatment schedule, Chow
et al. have recently published an update on the systematic review
of palliative radiotherapy [11]. In their meta-analysis, they com-
pared single and multiple fraction treatment and determined that
there is no difference between the response rates of single fraction
(60% overall response, 23% complete response), and multiple
fraction treatments (61% overall response, and 24% complete
response). Pathological fracture and spinal cord compression rates
were not statistically different between either arm; however, the
likelihood of requiring retreatment was 2.6 times higher in the
single fraction arm [11]. Thus, it was recommended that a single
8 Gy fraction be used to treat all patients with uncomplicated bone
metastases.
2.2. Reluctance to practice evidence-based medicine
There have been a number of systematic reviews and meta-
analyses to determine which treatment is more beneﬁcial for
patients with painful uncomplicated bone metastases [10–12]. Of
which, it has been determined that there is no difference between
single and multiple fractions in terms of pain response. Thus, it has
been recommended that physicians prescribe single fraction
treatment to patients with uncomplicated bone metastases where
possible. However, a reluctance to practice evidenced based
medicine still exists [13,14].2.2.1. Which regimen?
Although it has been recommended that a single 8 Gy fraction
be employed for patients with painful uncomplicated bone metas-
tases, the majority of radiation oncologists are still treating
patients with multiple fraction regimens [14]. In Canada, the most
common fractionation delivered to patients is 20 Gy in 5 fractions,
and among American radiation oncologists it is 30 Gy in 10
fractions [14]. Another study on the international patterns of
practice has globally demonstrated that despite the abundance
of evidence, radiation oncologists still prescribe multi-fractionated
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tases [13]. Roos et al. have also reported the continuing reluctance
to use single fraction radiation therapy in their group of radiation
oncologists in New Zealand and Australia [15].
Recently, ASTRO has published an evidence-based guideline to
better help physicians in their prescription of treatment for
individuals with painful uncomplicated bone metastases. The
guideline states that external beam radiation be used for the
treatment of bone metastases and that a single 8 Gy should be
employed where possible. They also state that no further clinical
trials are required to conﬁrm that a single treatment should be
used in these circumstances [16].
To further bring attention to this reluctance, a number of
editorials have been published that address this issue [17–19].
These authors question the reasoning of radiation oncologists who
continue to employ multi-fractionated schedules when it is known
that a single fraction holds the same efﬁcacy. Chow et al.
suggest that single fraction radiotherapy should be adopted as
department policy in order to maximize social justice by decreas-
ing wait times [19].
2.2.2. Retreatment fractionation
There currently is no recommended retreatment fractionation;
however a Canadian study is assessing this research question. A
National Cancer Institute of Canada clinical trial (NCIC CTG SC 20)
has closed accrual and is analyzing the results. This study rando-
mized patients between a single 8 Gy and 20 Gy in 5 or 8 fractions
for retreatment. Patients completed a follow-up assessment every
month for 6 months after the start of radiation, and months 9 and
12. Follow-up assessments included a pain and medication assess-
ment. Arm one included a single 8 Gy treatment, and arm two was
comprised of 20 Gy in 5 fractions or 20 Gy in 8 fractions for spine
retreatment. The planned sample size for this trial was 850
patients.
A correlational study, SC20U, took place in conjunction with
this retreatment study. The correlational study was used to
determine the effect of re-irradiation for bone pain on urinary
markers of osteoclast activity. Previous study in this area with
breast and prostate bone metastases patients demonstrated that
pyridinoline and deoxypridinoline levels in those who responded
to treatment were lower at baseline than those who did not
respond. 4 weeks post treatment, levels in responders only
slightly increased, while levels in nonresponders dramatically
increased [20].
The results of these two studies are greatly anticipated, and
perhaps may be able to provide further insight into the most
appropriate radiation therapy fractionation regimen for retreat-
ment of bone metastases.3. Difference in physician vs. patient perspectives
It has been identiﬁed in a number of trials that patient and
physician preferences differ. Often times, patients have different
wants and needs for treatment and do not value the same aspects
of treatment as do physicians.
3.1. Treatment preferences
A trial conducted by Szumacher et al. assessed patient pre-
ference of treatment with palliative radiation therapy for bone
metastases. The purpose of this trial was to determine the
proportion of patients who wanted to partake in the decision-
making process and to determine the proportion of patients who
preferred 8 Gy in 1 fraction to 20 Gy in 5 fractions. The majority of
patients determined they wanted to decide either by themselvesor with their radiation oncologist on which treatment option they
preferred. 8 Gy in 1 fraction was the preferred treatment regimen
regardless of site treated. The convenience of this treatment and
the likelihood of bone fracture were the most important inﬂuen-
cing factors on the patient's decision [21].
3.2. QOL perspectives
With the main goal of palliative radiotherapy for bone metas-
tases being to alleviate symptoms and improve quality of life, a
way to determine quality of life and issues prevalent to patients is
essential. Thus, key issues to bone metastases patients have been
determined through a number of studies pertaining to the devel-
opment of a quality of life questionnaire designed speciﬁcally for
this patient population [22–25].
The objective for the development of this tool was to develop a
set of items and scales for assessing quality of life issues not
sufﬁciently covered by the European Organization for Research
and Treatment of Cancer (EORTC) quality of life questionnaire core
30 (QLQ-C30). Disease symptoms, side-effects, complications and
other issues related to treatment of bone metastases are included
in this bone metastases module, the EORTC QLQ-BM22 [26]. The
development of this module underwent four phases: generation of
relevant QOL issues, operationalization of the QOL issues into a set
of items, pre-testing of the module questionnaire, and large scale
international ﬁeld testing.
Generation of relevant QOL issues included literature searches,
interviews with health care professionals (HCPs) and patient
interviews. This yielded a 61 item list that was then formatted
into a questionnaire. 413 patients then completed the question-
naire rating the relevancy of each item from 1 (not relevant) to 4
(very relevant). Patients also determined if each item should be
included in the ﬁnal module (yes/no) and picked their top 5–10
items [23]. Top 10 QOL issues for patients included long-term
chronic pain, psychological issues and worry about losing inde-
pendence, while the majority of issues selected by HCPs were
associated with pain [27]. A study by Harris et al. on the
comparison of HCP and patient responses to the BM22 outlines
the signiﬁcant differences between patient and HCP ideals of QOL
issues pertinent to bone metastases patients [27].
The ﬁnal QOL module includes four sections that patients and
HCPs have agreed upon: painful sites, painful characteristics,
functional interference and psychological aspects. This module
has successfully undergone validation testing and should be
utilized in bone metastases clinical trials [24]. It has also under-
gone meaningful change testing to determine the degree of change
that is meaningful to patients, the point at which they consider
their symptoms to have improved or deteriorated [22].
This study demonstrated the failure of physicians in choosing
items that are relevant to patients. It demonstrates the disparity
between patient and HCP thoughts on QOL issues, and promotes
the inclusion of patients in these decision making processes.4. Challenges
4.1. Improve side effects
There are a number of side effects associated with radiation
treatment for bone metastases. Most commonly, patients experi-
ence pain ﬂare, and/or radiation induced nausea and vomiting.
4.1.1. Pain ﬂare
Pain ﬂare is one of the most common side effects associated
with radiation therapy of bone metastases. It occurs in up to 40% of
patients who receive conventional radiation treatment and up to
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Pain ﬂare is deﬁned as a 2-point increase in the worst pain score
on a 0–10 scale in comparison to baseline with no decrease in
analgesic intake, or a 25% analgesic intake increase with no
decrease in worst pain score [28]. Typically, this pain ﬂare occurs
within the ﬁrst 10 days following treatment. This side effect however
can be reduced and treated. In a phase II study by Hird et al., it was
concluded that a single dose of dexamethasone is quite effective in
the prophylaxis of radiation-induced pain ﬂare [29].
Dexamethasone as a prophylactic treatment against pain ﬂare
has been proven effective. For a single 8 Gy treatment, 8 mg of
dexamethasone before treatment and for 3 days after radiation has
greatly reduced pain ﬂare rates. With this prescription, patients
have pain ﬂare free rates of 83% on days 1–5 post-treatment and
95% on days 6 through 10 post-treatment [30]. In the phase II
study by Hird et al. only 9 of 41 patients experienced a pain ﬂare,
and most commonly ﬂares occurred on day 5 post-treatment [30].
In order to create a change in standard of practice, the
prophylaxis of dexamethasone is now undergoing a phase III
double-blind placebo controlled study through the National Can-
cer Institute of Canada (NCIC) Clinical Trials Group (CTG). In this
study (NCIC CTG SC 23), eligible patients who are receiving a single
8 Gy radiation treatment for painful uncomplicated bone metas-
tases are randomized to receive either placebo or dexamethasone.
Patients take the medication 1 h prior to treatment and once a day
for 4 days following treatment. A 10 day pain diary is then
completed to record pain scores and medication. Patients also
complete the EORTC QLQ-BM22, QLQ-C15-Pal and a dexametha-
sone questionnaire at baseline, day 10 post-treatment and day 42
post-treatment. The expected sample size for this trial is approxi-
mately 250 patients.4.1.2. Radiation-induced nausea vomiting
Radiation-induced nausea and vomiting (RINV) occurs in an
estimated 40–80% of patients undergoing radiation therapy. The
incidence rate depends on the anatomical region irradiated and
the treatment volume [31]. In a study by Dennis et al., patients
undergoing moderately emetogenic radiation therapy were pre-
scribed Ondanestron and daily rates of nausea and vomiting were
collected. Daily incidence rates of at least one episode of nausea
ranged from 19% to 44% and daily incidence rates of at least one
episode of vomiting ranged from 0% to 25% [31]. Through this
study it was concluded that despite prophylaxis, RINV affected a
signiﬁcant portion of patients undergoing radiation therapy for
bone metastases.
To better prevent this side effect, our group is conducting a
phase II study with Granisetron and Aprepitant for prophylaxis
against RINV. Early analysis of this cohort shows that less than 30%
of patients undergoing single fraction radiation experience any
nausea or vomiting, and less than 33% of patients undergoing
multiple fraction radiation experience nausea or vomiting up to 10
days post-treatment.
The outcomes of these two studies on pain ﬂare and RINV are
greatly anticipated to determine a remedy for this side-effect
challenge of radiation therapy treatment.
4.2. Evaluating radiosurgery
Stereotactic body radiotherapy (SBRT) has increasingly become
more common in the management of spinal metastases. A recent
systematic review of 31 studies utilizing SBRT for spinal metas-
tases has quoted an overall local control rate of 90% [32]. It was
concluded that spine SBRT was highly effective in reducing pain
regardless of prior treatment, and this type of treatment may be
preferred in those patients who have been previously receivedtreated and radiation tolerance of the spinal cord is a concern. It
was concluded that any complications associated with SBRT were
self-limited and mild [32].
Additional challenges with spine SBRT have been evident in the
literature. The most drastic complication is vertebral compression
fractures that can occur after spine SBRT. Fracture rates in patients
who underwent spine SBRT were fairly high. One retrospective
study identiﬁed 11% of patients treated with spine SBRT who
subsequently developed a fracture [33]. The median follow-up
time was 7.4 months. Another study reported a fracture rate of 39%
in their patients post-SBRT [34]. Patients who experienced frac-
tures were more likely to have higher pain scores and subse-
quently had a decrease in performance status.
In addition to high rates of vertebral compression fracture,
spine SBRT also has high rates of pain ﬂare. In one study of pain
ﬂare after SBRT for bone metastases, it was determined that 66% of
patients experienced a ﬂare, most commonly on the ﬁrst day post-
treatment [35]. Patients who underwent a single treatment had a
slightly higher incidence (71%) than those who received multiple
fractions (63%). It was also noted that patients who were on
steroids prior to SBRT did not have a pain ﬂare.
Although spine SBRT may appear to be a superior treatment
than palliative radiotherapy for patients with bone metastases,
there are a number of adverse events that are not as widely
studied and documented. Physicians need to take these limitations
and adverse events into consideration before treating patients
with this approach.
4.3. How to integrate ultrasound/MRI with external beam radiation
High intensity focused ultrasound (HIFU) has proven to be
effective in the treatment of solid tumors. Utilizing energy levels
much higher than the diagnostic dose, it is a noninvasive treatment
that utilizes high frequencies to ablate tumors. During treatment, the
temperature at the focus can rise rapidly to above 80 1C, which
effectively kills cells [36]. A pilot study of 10 patients with bone
metastases treated with HIFU has been completed at the Sunnybrook
Odette Cancer Centre, and results are greatly anticipated.
Another new way to use ultrasound to enhance radiation has
been discovered; microbubbles passed through the body's circula-
tion. Normally used as a contrast agent for ultrasound to detect
cancer or new growth, in this study microbubbles are used as
resonating agents inside the tumor blood vessels to destabilize
structures and create greater sensitivity to low doses of radiation.
With these microbubbles, a 40%–50% tumor volume cell death after a
single 2 Gy radiation dose combined with ultrasound and micro-
bubbles can be achieved [37]. This is compared to a 5% cell death
utilizing microbubbles and ultrasound alone. Thirty-ﬁve 2 Gy treat-
ments are required to achieve a comparable cell death [38]. This is an
exciting new area of research that scientists are actively pursuing.
Perhaps in the future, it will be possible to treat bone metastases
patients with very low doses of radiation in the presence of
ultrasound and microbubbles in hopes of ablating tumors.
Radiation oncologists and ultrasound imaging radiologists will
need to work together in order to best treat patients with these
new techniques.
4.4. Treating metastatic cancer with nanotechnology
Nanoparticles are becoming more common in the ﬁeld of
medicine. In a recent review, authors have outlined the current
status of these particles and their role in cancer treatment [39].
With these particles, different biological pathways are stimulated
and apoptosis can be achieved. Greater knowledge of these
particles and how they operate is required before treatment with
nanotechnology can be adopted into daily practice.
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overall improved survival by 44% in patients with bone metastases
from castrate resistant prostate cancer [40]. This treatment pro-
longed median time to ﬁrst skeletal related event by 64%. There
appears to be a beneﬁt in using these new technologies, however
radiation oncologists will need to work alongside other health care
professionals in order to deliver the most effective and up to date
treatment to their patients.5. Conclusion
There are a number of failures and challenges to treating patients
with radiation therapy for bone metastases. In the future, there will
need to be great collaboration between health care professionals in
order to effectively determine the optimal treatment for this patient
population. It is hoped that through collaboration, upcoming new
treatments will be further developed, and new methods for treatment
will be discovered. In themeantime, radiation oncologists should work
to ﬁnd solutions to the current failures of radiation therapy, and
consciously work towards practicing evidence based medicine.Conﬂict of Interest Statement
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